A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer

Kasinski, Andrea L.; Kim, Kevin; Stahlhut, Carlos; Orellana, Esteban A.; Zhao, Jane; Shimer, Eliot; Dysart, Sarah; Chen, Xiaowei; Bader, Andreas G.; Slack, Frank J.

doi:10.1038/onc.2014.282

Cited by 180 publications

(185 citation statements)

References 34 publications

(45 reference statements)

Supporting

Mentioning

182

Contrasting

Order By: Relevance

“…All these lines of evidence open up the possibility to target multiple players of the same pathway and give hope for combined therapeutic interventions. In line with this hypothesis, it has recently been shown that the simultaneous systemic delivery of two small non-coding RNAs acting as tumor suppressors, miR-34 and let-7, leads to reduced non-small lung cancer growth (33).…”

Section: Discussionmentioning

confidence: 83%

miR-214 and miR-148b Targeting Inhibits Dissemination of Melanoma and Breast Cancer

et al. 2016

View full text Add to dashboard Cite

miR-214 and miR-148b have been proposed to antagonize the effects of each other in enabling or blocking metastasis, respectively. In this study, we provide evidence deepening their role and interrelationship in the process of metastatic dissemination. Depleting miR-214 or elevating miR-148b blocked the dissemination of melanoma or breast cancer cells, an effect that could be accentuated by dual alteration. Mechanistic investigations indicated that dual alteration suppressed passage of malignant cells through the blood vessel endothelium by reducing expression of the cell adhesion molecules ITGA5 and ALCAM. Notably, transendothelial migration in vitro and extravasation in vivo impaired by singly alternating miR-214 or miR-148b could be overridden by overexpression of ITGA5 or ALCAM in the same tumor cells. In clinical specimens of primary breast cancer or metastatic melanoma, we found a positive correlation between miR-214 and ITGA5 or ALCAM along with an inverse correlation of miR-214 and miR-148b in the same specimens. Our findings define an antagonistic relationship of miR-214 and miR-148b in determining the dissemination of cancer cells via tumor-endothelial cell interactions, with possible implications for microRNA-mediated therapeutic interventions aimed at blocking cancer extravasation.

show abstract

Section: Discussionmentioning

confidence: 83%

miR-214 and miR-148b Targeting Inhibits Dissemination of Melanoma and Breast Cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…10,11 LncRNA-MALAT-1 was up-regulated during the tumourigenesis of lung cancer and demonstrated to be associated with metastasis in NSCLC patients. 12 Fas apoptotic inhibitory molecule 2 (FAIM2) could inhibit Fas-mediated cell death and was found to be overexpressed in SCLC cell lines.…”

mentioning

confidence: 99%

miR‐193b availability is antagonized by LncRNA‐SNHG7 for FAIM2‐induced tumour progression in non‐small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

Objectives: Long non-coding RNAs have identified to involve into the tumour cell proliferation, apoptosis and metastasis. We previously found that up-regulated LncRNA-SNHG7 (SNHG7) positively correlated to the Fas apoptosis inhibitory molecule 2 (FAIM2) in lung cancer cells with unclear mechanism.Methods: Non-small cell lung cancer (NSCLC) and relative normal tissues (n = 25) were collected. The SNHG7 expression and function in NSCLC was determined. The SNHG7-miR 193b-FAIM2 network was analysed in vitro and vivo.Results: We reported that oncogene SNHG7 predicted a poor clinical outcome and functioned as competitive endogenous RNA (ceRNA) antagonized microRNA-193b Conclusion:The results indicated that miR-193b is indispensible for the ceRNA role of SNHG7 in FAIM2-supported tumourigenesis of lung cancer.

show abstract

“…Two miRNA mimics (miR-34 and let-7) targeting oncogenes implicated in the development of solid tumors are presently in preclinical development [195]. miRNA antagonists are also of interest, with candidates under development: three miRNAs (miR-195 et miR-208/499) in preclinical targeting CVD and one miRNA (miR-122) in phase II clinical trial targeting hepatitis C viral infection [196,197].…”

Section: Therapymentioning

confidence: 99%

microRNAs in lipoprotein and lipid metabolism: from biological function to clinical application

Desgagné

Bouchard

Guérin

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

microRNAs (miRNAs) are short (~ 22 nucleotides), non-coding, single-stranded RNA molecules that regulate the expression of target genes by partial sequencespecific base-pairing to the targeted mRNA 3′UTR, blocking its translation, and promoting its degradation or its sequestration into processing bodies. miRNAs are important regulators of several physiological processes including developmental and metabolic functions, but their concentration in circulation has also been reported to be altered in many pathological conditions such as familial hypercholesterolemia, cardiovascular diseases, obesity, type 2 diabetes, and cancers. In this review, we focus on the role of miRNAs in lipoprotein and lipid metabolism, with special attention to the well-characterized miR-33a/b, and on the huge potential of miRNAs for clinical application as biomarkers and therapeutics in the context of cardiometabolic diseases.

show abstract

A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer

Cited by 180 publications

References 34 publications

miR-214 and miR-148b Targeting Inhibits Dissemination of Melanoma and Breast Cancer

miR-214 and miR-148b Targeting Inhibits Dissemination of Melanoma and Breast Cancer

miR‐193b availability is antagonized by LncRNA‐SNHG7 for FAIM2‐induced tumour progression in non‐small cell lung cancer

microRNAs in lipoprotein and lipid metabolism: from biological function to clinical application

Contact Info

Product

Resources

About